Pharmacokinetics of guanfacine in patients undergoing haemodialysis

[1]  A. Jäättelä.  Clinical efficacy of BS 100-141 in essential hypertension , 2004, European Journal of Clinical Pharmacology.

[2]  P. Jerie,et al.  Guanfacine in the treatment of hypertension: two years' experience with low dose monotherapy. , 1981, International journal of clinical pharmacology, therapy, and toxicology.

[3]  W. Braun,et al.  The Influence of Renal Function on Plasma Concentration, Urinary Excretion and, Antihypertensive Effect of Guanfacine , 1980, Clinical pharmacokinetics.

[4]  Y. Seedat.  Long-term treatment of hypertension with guanfacine alone and in combination therapy. , 1980, British journal of clinical pharmacology.

[5]  W. Braun,et al.  Elimination of guanfacine in patients with normal and impaired renal function. , 1980, British journal of clinical pharmacology.

[6]  J. Kiechel.  Pharmacokinetics and metabolism of guanfacine in man: a review. , 1980, British journal of clinical pharmacology.

[7]  W. Kirch,et al.  Antihypertensive effect of N-amidino-2-(2,6-dichlorophenyl) acetamide hydrochloride. A double-blind cross-over trial versus clonidine. , 1978, International journal of clinical pharmacology and biopharmacy.

[8]  G. Scholtysik,et al.  Pharmacological actions of the antihypertensive agent N-amidino-2-(2,6-dichlorophenyl)acetamide hydrochloride (BS 100-141). , 1975, Arzneimittel-Forschung.

[9]  G. Scholtysik,et al.  Substituted phenylacetylguanidines: a new class of antihypertensive agents. , 1975, Arzneimittel-Forschung.